Kala’s Third Phase III Trial Should Line Up Approval In Dry Eye

 
• By Joseph Haas

Data showing that endpoints were met for both signs and symptoms of dry eye disease should position Kala’s KRI-121 for US approval. The company hopes to differentiate with short-term flare treatment.

Concept of eyesight, closeup of one eye with a target centred
Kala is targeting approval of Eysuvis by year's end in dry eye disease

More from New Products

More from Scrip